Skyrizi (risankizumab-rzaa) is a biologic medication doctors prescribe to treat certain autoimmune and inflammatory conditions. Like any medication, it can cause side effects. But is one of Skyrizi’s ...

After a 2024 in which AbbVie’s Skyrizi boasted the highest TV drug ad spending outlay on seven of our monthly roundups—and took second place in four more—the immunology med has seen that dominance ...

It was déjà vu all over again for TV drug ad spending in August, as the top 10 spenders barely deviated from July’s list and turned in a combined total nearly identical to the preceding month’s haul.

AbbVie’s Skyrizi took home the top spot for most pharma brand ad impressions in April, according to data released by iSpot.tv on Wednesday afternoon. The psoriasis treatment garnered an impressions ...

Skyrizi came out with the largest Q2 impressions share of voice (SOV) spot for over-the-counter (OTC) pharma and Rx brands for the second year in a row, according to iSpot.tv data released this week.

The use of interleukin (IL)-23 inhibitors plays an important role in treating patients with psoriasis, as well as in treating ...

AbbVie ABBV expects to return to robust revenue growth in 2025, just two years after losing U.S. exclusivity for its flagship drug, Humira. The drug, which went off-patent in January 2023, saw ...

AbbVie ABBV delivered encouraging second-quarter 2025 results last week, sending a clear message — it is effectively managing its post-Humira transition. The stronger-than-expected sales of newer ...